These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22554615)

  • 21. Evaluations of organ system development in juvenile toxicology testing.
    Robinson K
    Reprod Toxicol; 2008 Sep; 26(1):51-3. PubMed ID: 18595655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testing strategies for embryo-fetal toxicity of human pharmaceuticals. Animal models vs. in vitro approaches: a workshop report.
    van der Laan JW; Chapin RE; Haenen B; Jacobs AC; Piersma A
    Regul Toxicol Pharmacol; 2012 Jun; 63(1):115-23. PubMed ID: 22449444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Innovative cell culture methods in drug development].
    Schleger C; Krebsfaenger N; Kalkuhl A; Bader R; Singer T
    ALTEX; 2001; 18(1):5-8. PubMed ID: 11248842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A different approach to validating screening assays for developmental toxicity.
    Daston GP; Chapin RE; Scialli AR; Piersma AH; Carney EW; Rogers JM; Friedman JM
    Birth Defects Res B Dev Reprod Toxicol; 2010 Dec; 89(6):526-30. PubMed ID: 21086491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary hepatocyte cultures for pharmaco-toxicological studies: at the busy crossroad of various anti-dedifferentiation strategies.
    Fraczek J; Bolleyn J; Vanhaecke T; Rogiers V; Vinken M
    Arch Toxicol; 2013 Apr; 87(4):577-610. PubMed ID: 23242478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical efficacy and safety models for mAbs: the challenge of developing effective model systems.
    Dixit R; Coats S
    IDrugs; 2009 Feb; 12(2):103-8. PubMed ID: 19204884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The application of human embryonic stem cell technologies to drug discovery.
    Sartipy P; Björquist P; Strehl R; Hyllner J
    Drug Discov Today; 2007 Sep; 12(17-18):688-99. PubMed ID: 17826681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real life juvenile toxicity case studies: the good, the bad and the ugly.
    De Schaepdrijver L; Rouan MC; Raoof A; Bailey GP; De Zwart L; Monbaliu J; Coogan TP; Lammens L; Coussement W
    Reprod Toxicol; 2008 Sep; 26(1):54-5. PubMed ID: 18514481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of body-on-a-chip devices in drug and toxicity studies.
    Esch MB; King TL; Shuler ML
    Annu Rev Biomed Eng; 2011 Aug; 13():55-72. PubMed ID: 21513459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microfluidic cell culture systems for drug research.
    Wu MH; Huang SB; Lee GB
    Lab Chip; 2010 Apr; 10(8):939-56. PubMed ID: 20358102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microelectrode arrays: a physiologically based neurotoxicity testing platform for the 21st century.
    Johnstone AF; Gross GW; Weiss DG; Schroeder OH; Gramowski A; Shafer TJ
    Neurotoxicology; 2010 Aug; 31(4):331-50. PubMed ID: 20399226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
    Srinivas NR
    Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dogs and monkeys in preclinical drug development: the challenge of reducing and replacing.
    Pellegatti M
    Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1171-80. PubMed ID: 23705836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-Throughput Cell Toxicity Assays.
    Murray D; McWilliams L; Wigglesworth M
    Methods Mol Biol; 2016; 1439():245-62. PubMed ID: 27317000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimisation of the cell cultivation methods in the embryonic stem cell test results in an increased differentiation potential of the cells into strong beating myocard cells.
    De Smedt A; Steemans M; De Boeck M; Peters AK; van der Leede BJ; Van Goethem F; Lampo A; Vanparys P
    Toxicol In Vitro; 2008 Oct; 22(7):1789-96. PubMed ID: 18672049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Juvenile animal toxicity study designs to support pediatric drug development.
    Cappon GD; Bailey GP; Buschmann J; Feuston MH; Fisher JE; Hew KW; Hoberman AM; Ooshima Y; Stump DG; Hurtt ME
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):463-9. PubMed ID: 20025047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting safety toleration of pharmaceutical chemical leads: cytotoxicity correlations to exploratory toxicity studies.
    Benbow JW; Aubrecht J; Banker MJ; Nettleton D; Aleo MD
    Toxicol Lett; 2010 Sep; 197(3):175-82. PubMed ID: 20576494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zebrafish embryos and larvae: a new generation of disease models and drug screens.
    Ali S; Champagne DL; Spaink HP; Richardson MK
    Birth Defects Res C Embryo Today; 2011 Jun; 93(2):115-33. PubMed ID: 21671352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments.
    Astashkina A; Grainger DW
    Adv Drug Deliv Rev; 2014 Apr; 69-70():1-18. PubMed ID: 24613390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.